Context Therapeutics Inc. (CNTX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Context Therapeutics Inc. (CNTX:NASDAQ), powered by AI.

Current Price
$0.65
P/E Ratio
-1.7
Market Cap
62M
Sector
Healthcare
What is the Context Therapeutics Inc. stock price forecast?

Context Therapeutics Inc. is currently trading at $0.65. View real-time AI analysis on Alpha Lenz.

What is Context Therapeutics Inc. insider trading activity?

View the latest insider trading data for Context Therapeutics Inc. on Alpha Lenz.

What is Context Therapeutics Inc.'s P/E ratio?

Context Therapeutics Inc.'s P/E ratio is -1.7.

Context Therapeutics Inc.

NASDAQ · CNTX
$0.65-0.03(-4.23%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Context Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Context Therapeutics Inc. trades at a P/E of -1.7 (undervalued) with modest ROE of -46.4%.

Ask for details

Company Overview

Context Therapeutics Inc. is a biopharmaceutical company focused on advancing treatments for hormone-driven female cancers. Primarily, the company develops investigational therapies targeting estrogen receptors, aiming to innovate in areas of significant unmet medical need. Context Therapeutics operates within the life sciences and biotechnology sectors, engaging in research and development to combat cancers like breast and ovarian cancer. The company's approach involves optimizing therapeutic outcomes through cutting-edge research, clinical trials, and strategic collaborations. With a strong commitment to patient-centered care, Context Therapeutics impacts the healthcare industry by striving to provide more effective and personalized treatment options for female cancer patients. Established in an era of increased focus on women's health, Context Therapeutics plays a vital role in the continued evolution and enhancement of oncology treatment solutions in the financial market.

CEOMr. Martin A. Lehr
SectorHealthcare
IndustryBiotechnology
Employees12

Company Statistics

FY 2025

Profile

$61.90MMarket Cap
$0.00Revenue
0.00Shares Out
12Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-1.71P/E
1.02P/B
N/AEV/Sales
0.10EV/EBITDA
-2.18P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-43.36%ROA
-46.39%ROE
-47.66%ROIC

Financial Health

$66.00MCash & Cash Equivalents
$-57.98MNet Debt
13.26%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Context Therapeutics Inc. (ticker: CNTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 12 employees. Market cap is $62M.

The current price is $0.65 with a P/E ratio of -1.71x and P/B of 1.02x.

ROE is -46.39%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Context Therapeutics Inc. (CNTX) Stock Forecast 2026 $0.65 — Price, Financials & Analyst Targets | Alpha Lenz